HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mark

This article was originally published in The Rose Sheet

Executive Summary

Claudia Poccia is appointed president of Avon's teen targeted cosmetics brand, effective Nov. 1, firm reports. Exec replaces Deborah Fine, who departed mark in January to head Limited Brands' Pink division (1"The Rose Sheet" Jan. 24, 2005, p. 8). Poccia will "lead mark's continuing growth in the United States and spearhead mark's international rollout," Avon says. She will report to Executive VP and President North America Brian Connolly. Poccia previously served as senior VP and general manager of Estee Lauder's Stila brand, where she helped improve the line's visibility with 17-34 year olds, according to Avon. Appointment marks exec's second position with Avon; she was director of field marketing from 1992-1994 before joining Estee Lauder. She also has worked at Giorgio Bevery Hills and L'Oréal...

You may also be interested in...



Limited Brands Reorganization Aims To Accelerate Growth

Limited Brands is reorganizing the company into three business groups - beauty and personal care, lingerie and apparel - in an effort to drive future growth, the Columbus, Ohio company announced Jan. 18

Roche's Tecentriq Disappoints In Ovarian Cancer Study

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.

Greater Uptake Must Become Belgium’s ‘New Normal’

Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel